Navigation Links
Nerve Conduction Studies Safe for Patients with Implanted Cardiac Devices

Patients with implanted cardiac devices and their physicians sometimes defer important electrodiagnostic testing because of anxiety about potential negative effects// the testing may have on the device. Good news for these patients and physicians is that according to recent research, electrodiagnostic testing was found to pose minimal or no risk to patients with implanted cardiac devices such as permanent pacemakers and implanted cardiac defibrillators.

Nerve conduction studies (NCSs) are done to detect and evaluate damage to the peripheral nervous system, which includes all the nerves that lead away from the brain and spinal cord and the smaller nerves that branch out from those nerves. Nerve conduction studies are often used to help diagnose nerve disorders, such as carpal tunnel syndrome or Guillain-Barre syndrome, and find the location of abnormal sensations, such as numbness, tingling, or pain.

The prevailing view among electrodiagnostic physicians and cardiac electrophysiologists, is that electrodiagnostic testing on patients with implanted cardiac devices is safe as long as the electrical stimulation is not given in direct proximity to the pulse generator of the cardiac device. Recording from intracardiac sensing electrodes during NCSs, which has not been previously reported, would be the best test to assess safety.

In a recent study, 10 patients with permanent bipolar pacemakers of various makes and 5 patients with implanted cardiac defibrillators (ICD) underwent nerve stimulation at sites commonly used during NCSs. The electrical impulses generated during routine NCSs were never detected by the sensing amplifier of the pacemaker or defibrillators. The NCS did not affect the programmed pacemaker or defibrillator settings and did not cause the defibrillator to discharge. The pacemaker and defibrillator were interrogated before and after NCSs and surface electrocardiogram and atrial and ventricular electrograms were continuo usly monitored during NCSs.

The research concluded that routine NCSs are safe in patients with implanted cardiac pacemakers and defibrillators with bipolar sensing configurations.

Source-Newswise
'"/>




Related medicine news :

1. Epilepsy Drug Helps Diabetic Nerve Damage
2. World’s First Nerve Stem Cells Produced
3. Children With Epilepsy Can Be Treated With Nerve Stimulation
4. FDA Approved Nerve-Stimulation Therapy Now Available In New York
5. Doctors Finish Mother-To-Son Nerve Surgery
6. Stem Cells From Hair Follicle To Repair Nerve Damage
7. Nerve regeneration for Spinal cord injuries
8. Novel Protein, Staufen2 Important In Maintenance Of Nerve Synapses
9. Dividing Nerve Cells Could Trigger Alzheimers Disease
10. Protein Found to Be Essential For Maintaining Nerve Health
11. Nerve Stimulator for Depression Though Not Effective Was Given Approval
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: